Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

By afschroeder • September 5, 2026

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs). J Cancer Surviv. 2026 Sep 4. doi: 10.1007/s11764-026-02109-y. Epub ahead of print. PMID: 42697984.

Tags: Cancer, Financial toxicity, Hematology/Oncology, mixed methods research, Publications, QUALITATIVE RESEARCH

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]

Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient[...]

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models

Anand SK, Das S, Arias F, Richard KS, Rohilla S, Ghrayeb A, McKinney MP, Wang L, Tan L, Ding J, Kumar D, Pandey N, Lee[...]